Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03105765
Other study ID # HSK007
Secondary ID
Status Completed
Phase N/A
First received August 12, 2016
Last updated April 3, 2017
Start date January 2011
Est. completion date August 2016

Study information

Verified date April 2017
Source Dr. Horst Schmidt Klinik GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic Pain, especially neuropathic pain, are adverse events after posterolateral thoracotomy for lung resection. The continuous application of ketamine may have a prophylactic effect and helps to prevent chronic pain. The investigators record the incidence and severity of acute pain and neuropathic pain during a seven day period after thoracotomy as well as the incidence of chronic pain and neuropathic pain after one and three month period. Parallel Group design, comparing one Group with a continuous application (24 hours) of ketamine against a Placebo Group.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date August 2016
Est. primary completion date August 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- posterolateral thoracotomy for lung parenchyma resection

- informed consent

- ASA (American Society of Anesthesiologists) Status I-III

Exclusion Criteria:

- history of chronic pain

- history of neuropathic pain

- pregnancy or breastfeeding

- participation in another trial

- hypersensitivity for ketamine

- medication with can influence neuropathic pain (gabapentin, clonazepam)

- history of neurological or behavioral illness

- history of alcohol abuse

- history of chemotherapy or radiation

- opioid medication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
Ketamine
Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.

Locations

Country Name City State
Germany Dr. Horst Schmidt Klinik Wiesbaden Hessen

Sponsors (1)

Lead Sponsor Collaborator
Dr. Horst Schmidt Klinik GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in perioperative opioid consumption The patients consumption of opioids is recorded once a day for a period of 7 days after operation. seven days after operation
Primary Change in acute pain The incidence and severity of pain will be measured using a numeric analog scale (NAS) once a day for a period of seven days after Operation. 7 days after Operation
Primary acute neuropathic pain The incidence of neuropathic pain will be measured using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) three and seven days after operation 7 days after operation
Secondary Change in chronic Pain The incidence and severity of pain will be measured using a numeric analog scale (NAS). Pain scale is requested by phone one and three month after Operation. one and three month after operation
Secondary Chronic Neuropathic pain The incidence of neuropathic pain will be measured by using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) one month after operation one month after operation
Secondary Chronic Neuropathic Pain The incidence of neuropathic pain will be measured by using the LANSS Pain Scale (Leeds assessment of neuropathic symptoms and signs) three month after operation three month after operation
Secondary recovery time Time between stopping intravenous anaesthesia and first eye opening of the Patient in minutes eye opening after stopping anesthesia in minutes
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain